Articles related to LUNG CANCER

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

Spectrum Pharmaceuticals would need to study the drug further, including generating data from a randomized controlled trial, according to the release. Spectrum responded by stating that it would “de-prioritize poziotinib program activities, effective immediately.” The decision comes after the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously that the drug’s demonstrated clinical benefit did not outweigh its risks.

A review of the seven zones/14 stations as defined by the International Association for the Study of Lung Cancer (IASLC): Supraclavicular zone Station 1 (left/right): low cervical, supraclavicular, and sternal notch nodes Upper zone (superior mediastinal nodes) Station 2 (left/right): upper paratracheal nodes Station 3A and 3P: pre-vascular and retrotracheal nodes Station 4 (left/right): lower paratracheal nodes Aortopulmonary zone Station 5: subaortic nodes (aortopulmonary window) Station 6: para-aortic nodes, ascending aorta or phrenic Subcarinal zone Station 7: subcarinal nodes Lower zone (inferior mediastinal nodes) Station 8 (left/right): para-esophageal nodes (below carina) Station 9 (left/right): pulmonary ligament nodes Hilar and interlobar zone (pulmonary nodes) Station 10 (left/right): hilar nodes Station 11: interlobar nodes Peripheral zone (pulmonary nodes) Station 12: lobar nodes Station 13: segmental nodes Station 14: subsegmental nodes

Four-hundred seventy-three of 713 patients were randomly assigned to receive durvalumab; 236 received a placebo. The 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The median progression-free survival from randomization was 16.8 months with durvalumab versus 5.6 months with placebo. Durvalumab had a response rate that was higher than placebo (28.4% vs. 16.0%), and the median response time was also longer (72.8% vs. 46.8% of the patients continued to have a response at 18 months). Durvalumab extended the median time to death or distant metastasis compared to placebo (23.2 months vs. 14.6 months). 29.9% of patients who received durvalumab and 26.1% of patients who received a placebo experienced adverse events of grade 3 or 4.

This approval was based on findings from the open-label, randomized, multicenter POSEIDON trial, which compared data from two of the study’s three treatment arms. When compared to patients in the other treatment arm, patients in this group had a significantly improved OS, with a median OS of 14 months as opposed to 11.7 months.

Neoadjuvant nivolumab plus chemotherapy improved event-free survival and increased the proportion of patients who had a pathological complete response in patients with resectable NSCLC compared to chemotherapy alone. Nivolumab was added to neoadjuvant chemotherapy, but neither the incidence of side effects nor the viability of surgery was affected.